Shares of the commercial-stage biopharmaceutical company highlighted in today’s article have nearly doubled since mid-March. The biggest reason why? The debut of the company’s hot new migraine drug, which it skillfully managed to launch despite patients avoiding visiting the doctor during the pandemic. What other factors are attracting investors to this company and driving up its stock price – including one “hidden factor”? CLICK HERE.